Oxaliplatin
Product Images NDC 47335-047

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Oxaliplatin (NDC 47335-047). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Oxaliplatin-carton-100mg (Oxaliplatin Carton 100mg)

Oxaliplatin Injection, USP 100 mg/20 mL (5 mg/mL) vial label by Sun Pharmaceutical Industries, Inc. The label states the product is a cytotoxic agent for intravenous use only, single-use vial, sterile and preservative-free. It includes storage instructions, warnings not to freeze or mix with sodium chloride solutions, and manufacturer information from Sun Pharmaceutical Industries Ltd., India. The label also shows the NDC 47335-047-40 and a barcode.*

FDA Label Image

Oxaliplatin-carton-50mg (Oxaliplatin Carton 50mg)

Carton label for Oxaliplatin Injection, USP 50 mg/10 mL (5 mg/mL) by Sun Pharmaceutical Industries, Inc. The label indicates the product is a cytotoxic agent for intravenous use only, provided as a sterile, preservative-free single-use vial. It includes storage instructions, dosage caution, and a barcode. The manufacturer is Sun Pharmaceutical Industries Ltd., Gujarat, India.*

FDA Label Image

Oxaliplatin-fig-1 (Oxaliplatin Fig 1)

An illustration showing a two-day chemotherapy schedule for Oxaliplatin and 5-FU infusion. On Day 1 and Day 2, leucovorin 200 mg/m² is given first, followed by a 5-FU bolus of 400 mg/m² over 2 to 4 minutes, then a 5-FU infusion of 600 mg/m². Oxaliplatin injection 85 mg/m² is given on Day 1. The timing intervals between doses are also displayed.*

FDA Label Image

Oxaliplatin-fig-2 (Oxaliplatin Fig 2)

A Kaplan-Meier survival curve chart depicting Disease-Free Survival (DFS) Probability over months. It compares two treatment arms, FOLFOX4 and LV5FU2, showing the number of events, hazard ratio, and number of patients at risk at various time points up to 72 months. The chart includes statistical results such as the stratified logrank test p-value and confidence intervals for the hazard ratio.*

FDA Label Image

Oxaliplatin-fig-3 (Oxaliplatin Fig 3)

A Kaplan-Meier survival curve chart showing DFS (Disease-Free Survival) Probability versus time in months up to 72 months. The chart compares two treatment arms, FOLFOX4 and LV5FU2, for Stage III, with a solid line for FOLFOX4 and a dashed line for LV5FU2. The graph includes hazard ratio and statistical data with a logrank test p-value.*

FDA Label Image

Oxaliplatin-fig-4 (Oxaliplatin Fig 4)

A survival curve graph depicting the percentage of patients surviving over 24 months for three treatments: Oxaliplatin Injection plus 5-FU/LV, Oxaliplatin Injection plus Irinotecan, and Irinotecan plus 5-FU/LV. Median survival times are 19.4, 17.6, and 14.6 months, respectively. The graph includes a statistical note indicating P<0.0001 by log-rank test comparing Oxaliplatin plus 5-FU/LV to Irinotecan plus 5-FU/LV.*

FDA Label Image

Oxaliplatin-label-100mg (Oxaliplatin Label 100mg)

Packaging label for Oxaliplatin Injection, USP, 100 mg/20 mL (5 mg/mL) single-use vial. The label specifies it as a cytotoxic agent for intravenous use only, sterile and preservative free, with storage and handling instructions. Manufactured by Sun Pharmaceutical Industries Ltd., India, and distributed by Sun Pharmaceutical Industries, Inc., Cranbury, NJ. Contains barcode and regulatory information.*

FDA Label Image

Oxaliplatin-label-50mg (Oxaliplatin Label 50mg)

The image shows a label for Oxaliplatin Injection, USP, with a strength of 50 mg/10 mL (5 mg/mL) supplied by Sun Pharmaceutical Industries, Inc. It is a sterile, preservative-free, single-use vial intended for intravenous use only. The label includes storage instructions, dosage notes, manufacturer details from Gujarat, India, and warnings against mixing with sodium chloride solutions.*

FDA Label Image

Oxaliplatin-structure (Oxaliplatin Structure)

Chemical structure of Oxaliplatin showing the platinum center coordinated to a 1,2-diaminocyclohexane ligand and oxalate group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.